A phase 2, open-label study of the combination of spartalizumab (PDR001) and LAG525 for patients with advanced solid tumors and hematologic malignancies

Autor:	Christina Kovacs, Andrea Magley, Das Purkayastha, Alpesh Amin, Sarina Anne Piha-Paul, Ying Zhuo
Rok vydání:	2018
Předmět:	0301 basic medicine Cancer Research medicine.drug_class business.industry Monoclonal antibody 03 medical and health sciences 030104 developmental biology 0302 clinical medicine Oncology Open label study 030220 oncology & carcinogenesis Immunoglobulin g4 medicine Cancer research business
Zdroj:	Journal of Clinical Oncology. 36:TPS2616-TPS2616
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2018.36.15_suppl.tps2616
Popis:	TPS2616Background: Spartalizumab is an immunoglobulin G4 humanized monoclonal antibody that binds with subnanomolar affinity to PD-1. LAG525 is an immunoglobulin G4 humanized monoclonal antibody th...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::3e566be008f1663ea82f6628003208c8 https://doi.org/10.1200/jco.2018.36.15_suppl.tps2616 Zobrazit plný text záznamu